AR081534A1 - Uso de la proporcion de agrandamiento ventricular para el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa y metodo para evaluar la eficacia terapeutica - Google Patents
Uso de la proporcion de agrandamiento ventricular para el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa y metodo para evaluar la eficacia terapeuticaInfo
- Publication number
- AR081534A1 AR081534A1 ARP110101285A ARP110101285A AR081534A1 AR 081534 A1 AR081534 A1 AR 081534A1 AR P110101285 A ARP110101285 A AR P110101285A AR P110101285 A ARP110101285 A AR P110101285A AR 081534 A1 AR081534 A1 AR 081534A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- alzheimer
- increase
- subject
- brain
- Prior art date
Links
- 230000002861 ventricular Effects 0.000 title abstract 7
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 238000001990 intravenous administration Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 210000004556 brain Anatomy 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 6
- 229940124597 therapeutic agent Drugs 0.000 abstract 6
- 238000004321 preservation Methods 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Developmental Disabilities (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
Reivindicación 1: Un método para tratar la enfermedad de Alzheimer en un sujeto que lo necesite, que comprende las etapas secuenciales de: (a) determinar el volumen ventricular en el cerebro del sujeto mediante imágenes por resonancia magnética (IRM), obteniéndose así un valor de referencia del volumen ventricular; (b) la administración de un agente terapéutico para la preservación del cerebro al sujeto con el fin de tratar la enfermedad de Alzheimer durante un primer periodo de tiempo; (c) determinar el volumen ventricular en el cerebro del sujeto mediante IRM, obteniéndose así un primer valor intermedio del volumen ventricular; (d) comparar el valor intermedio de la etapa (c) con el valor de referencia de la etapa (a); (e) aumentar la administración del agente terapéutico para la preservación del cerebro en dosis o frecuencia cuando la etapa (d) indica un aumento desde el valor de referencia al primer valor intermedio y el aumento es igual o mayor que un aumento esperado en el volumen ventricular en un sujeto con enfermedad de Alzheimer pero sin recibir tratamiento para la enfermedad dentro de un período de tiempo de la misma duración que el primer periodo de tiempo, o mantener la administración del agente terapéutico para la preservación del cerebro en dosis o frecuencia cuando la etapa (d) indica que no hay aumento desde el valor de referencia al primer valor intermedio o indica un aumento que es menor que el incremento esperado en el volumen ventricular en un sujeto con enfermedad de Alzheimer pero sin recibir tratamiento para la enfermedad dentro de un período de tiempo de la misma duración que el primer periodo de tiempo.Reivindicación 6: El método de la reivindicación 1, en donde el agente terapéutico es un agente terapéutico para la preservación del cerebro a base de inmunoglobulina. Reivindicación 7: El método de la reivindicación 1, donde el agente terapéutico es inmunoglobulina intravenosa (lglV).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32373910P | 2010-04-13 | 2010-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081534A1 true AR081534A1 (es) | 2012-10-03 |
Family
ID=44761427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101285A AR081534A1 (es) | 2010-04-13 | 2011-04-14 | Uso de la proporcion de agrandamiento ventricular para el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa y metodo para evaluar la eficacia terapeutica |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8066993B2 (es) |
| EP (1) | EP2451348A4 (es) |
| JP (2) | JP2013509985A (es) |
| KR (1) | KR20130114563A (es) |
| CN (1) | CN102946799A (es) |
| AR (1) | AR081534A1 (es) |
| AU (1) | AU2011240556B2 (es) |
| BR (1) | BR112012026224A2 (es) |
| CA (1) | CA2795651A1 (es) |
| CL (1) | CL2012002852A1 (es) |
| CO (1) | CO6592030A2 (es) |
| EA (1) | EA201291040A1 (es) |
| IL (1) | IL222245A0 (es) |
| MX (1) | MX2012011924A (es) |
| SG (1) | SG184820A1 (es) |
| TW (1) | TW201138807A (es) |
| WO (1) | WO2011130355A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090280114A1 (en) * | 2002-04-12 | 2009-11-12 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| EP2742855A1 (en) * | 2012-12-11 | 2014-06-18 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition |
| PT2994160T (pt) * | 2013-05-06 | 2019-08-07 | Baxalta Inc | Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada |
| CN106163548A (zh) * | 2014-02-08 | 2016-11-23 | 健泰科生物技术公司 | 治疗阿尔茨海默氏病的方法 |
| JP6548615B2 (ja) * | 2016-08-23 | 2019-07-24 | 富士フイルム株式会社 | 磁場歪み算出装置、方法およびプログラム |
| CN108830830A (zh) * | 2018-05-11 | 2018-11-16 | 深圳博脑医疗科技有限公司 | 一种脑萎缩程度的定量检测方法、检测装置及终端设备 |
| KR102276545B1 (ko) * | 2019-09-05 | 2021-07-15 | 고려대학교 산학협력단 | Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003064395A1 (ja) * | 2002-01-31 | 2005-05-26 | 国立精神・神経センター総長 | 神経変性疾患の予防又は治療剤 |
| BRPI0517672A (pt) * | 2004-11-05 | 2008-10-14 | Wyeth Corp | modalidades de formação de imagens para seleção terapêutica de doença de alzheimer |
| JP5889529B2 (ja) * | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
| ES2477294T3 (es) * | 2007-08-13 | 2014-07-16 | Baxter International Inc | Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
-
2011
- 2011-04-13 JP JP2012539095A patent/JP2013509985A/ja active Pending
- 2011-04-13 WO PCT/US2011/032232 patent/WO2011130355A1/en active Application Filing
- 2011-04-13 MX MX2012011924A patent/MX2012011924A/es not_active Application Discontinuation
- 2011-04-13 KR KR1020127029420A patent/KR20130114563A/ko not_active Application Discontinuation
- 2011-04-13 CN CN2011800191696A patent/CN102946799A/zh active Pending
- 2011-04-13 BR BR112012026224A patent/BR112012026224A2/pt not_active IP Right Cessation
- 2011-04-13 US US13/086,285 patent/US8066993B2/en not_active Expired - Fee Related
- 2011-04-13 EP EP11769496.8A patent/EP2451348A4/en not_active Withdrawn
- 2011-04-13 SG SG2012075479A patent/SG184820A1/en unknown
- 2011-04-13 AU AU2011240556A patent/AU2011240556B2/en not_active Ceased
- 2011-04-13 TW TW100112770A patent/TW201138807A/zh unknown
- 2011-04-13 CA CA2795651A patent/CA2795651A1/en not_active Abandoned
- 2011-04-13 EA EA201291040A patent/EA201291040A1/ru unknown
- 2011-04-14 AR ARP110101285A patent/AR081534A1/es unknown
- 2011-10-17 US US13/274,886 patent/US8722042B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 JP JP2012115203A patent/JP2012210413A/ja active Pending
- 2012-10-09 IL IL222245A patent/IL222245A0/en unknown
- 2012-10-11 CL CL2012002852A patent/CL2012002852A1/es unknown
- 2012-11-13 CO CO12203213A patent/CO6592030A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US8066993B2 (en) | 2011-11-29 |
| IL222245A0 (en) | 2012-12-31 |
| US8722042B2 (en) | 2014-05-13 |
| US20110251479A1 (en) | 2011-10-13 |
| CA2795651A1 (en) | 2011-10-20 |
| KR20130114563A (ko) | 2013-10-17 |
| SG184820A1 (en) | 2012-11-29 |
| AU2011240556B2 (en) | 2012-06-21 |
| JP2012210413A (ja) | 2012-11-01 |
| JP2013509985A (ja) | 2013-03-21 |
| CL2012002852A1 (es) | 2013-04-05 |
| EP2451348A4 (en) | 2013-07-31 |
| AU2011240556A1 (en) | 2012-04-19 |
| CO6592030A2 (es) | 2013-01-02 |
| TW201138807A (en) | 2011-11-16 |
| EA201291040A1 (ru) | 2013-04-30 |
| BR112012026224A2 (pt) | 2016-07-12 |
| WO2011130355A1 (en) | 2011-10-20 |
| MX2012011924A (es) | 2013-03-05 |
| CN102946799A (zh) | 2013-02-27 |
| EP2451348A1 (en) | 2012-05-16 |
| US20120071747A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081534A1 (es) | Uso de la proporcion de agrandamiento ventricular para el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa y metodo para evaluar la eficacia terapeutica | |
| Duffau | The dangers of magnetic resonance imaging diffusion tensor tractography in brain surgery | |
| CO2017010260A2 (es) | Un dispositivo para la reducción de oxígeno en sangre y método para preparar sangre con oxígeno reducido | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX2021013880A (es) | Polimeros enlazados al proton para administracion oral. | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| EA201690212A8 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| MY197091A (en) | Compositions for treating acid-base disorders | |
| EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
| MX2019014711A (es) | Polimeros de union a protones para administracion oral. | |
| MX2017001682A (es) | Composiciones de alergenos alimentarios. | |
| CO2017007383A2 (es) | Métodos para utilizar oligonucleótidos antisentido para smad7 | |
| GB2552630A (en) | System and method of stress reduction | |
| MX2019006141A (es) | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. | |
| JP2014201591A5 (es) | ||
| CY1120727T1 (el) | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου | |
| GB201121914D0 (en) | Method for patient selection | |
| Hashmi et al. | Thoracic cord compression by extramedullary hematopoiesis in thalassemia | |
| MX2019004200A (es) | Terapia de combinacion. | |
| EA201500137A1 (ru) | Способ лечения аддикции | |
| IL284432A (en) | A preparation for magnetic resonance imaging containing sarcosine containing deuterium, and a diagnostic method using the aforementioned preparation | |
| WO2016187397A3 (en) | System and method for assessing tissue after hypothermia | |
| Prakhova et al. | Neuroprotection therapy of multiple sclerosis with high doses of ethylmethylhydroxypyridine succinate | |
| EA201600229A1 (ru) | Бис(5-амино-1,4-диоксо-1,2,3,4-тетрагидрофталазин-2-ил)цинк, способ его получения, фармацевтическая композиция на его основе, лечебные средства на его основе, способ лечения кожных заболеваний и способ лечения гастрита | |
| Yi et al. | The Effect of Integrated Healthcare Program on Physical Activity for the for Laotian Non-communicable Diseases Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |